The conference highlighted progress in allogeneic CAR NK cell therapy for autoimmune diseases, with ongoing trials in lupus nephritis and other indications. Key updates include improved conditioning regimens, outpatient dosing, and a major data readout planned for 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.